A recent survey investigates the persistent American obsession with the Olympics.
Tebra's research asked 1,024 Americans and 92 medical professionals what they thought of Ozempic as a weight-loss supplement.
Novo Nordisk created Ozempic, a semaglutide injection, for people with type 2 diabetes.
In combination with diet and exercise, the FDA has approved Ozempic to help adults with type 2 diabetes better regulate their blood sugar levels.
Ozempic demands from Americans looking to lose weight are increasing, which has an impact on type 2 diabetes patients' requirements.
Some Americans are looking for alternatives to Ozempic because it is becoming harder to find.
Another semaglutide injectable created by Novo Nordisk with weight loss in mind is called Wegvoy.
Another choice is Eli Lilly's Mounjaro, which is gaining popularity.